PATENT CLAIM ANALYSIS

Application Number: 16014133
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-03
Patent Classification: ["435", "325000"]

Abstract:
The present invention provides compositions and methods for generating a genetically modified T cells comprising a chimeric antigen receptor (CAR) having an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain, wherein the T cell exhibits prolonged exponential expansion in culture that is ligand independent and independent of the addition of exogenous cytokines or feeder cells.

Claim (Index 24):
The vector of  claim 20 , wherein the transmembrane domain is a CD28 transmembrane domain, and/or wherein the costimulatory signaling region is a CD28 signaling region.

Metadata:
- Claim Count in Document: 46.0
- Percentile: 94.0
- Lexical Diversity: 1.34615
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14375015', '13992622', '15866222', '14984371', '14997136']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6646200188680482
- 35 USC 102 Novelty (BERT): 0.6387384702587184
- Combined Prediction Score: 0.6620318640071152
- Mean Citation Score: 519.5398600000002
- Max Citation Score: 666.8671
- Similarity Product: 540.2172848464072

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test